Table SI. Expression of PCNA in relation to clinicopathological features within the carcinomatous component of uterine carcinosarcomas.

| Parameter                             | n    | Expression level of PCNA | P-value |
|---------------------------------------|------|--------------------------|---------|
|                                       |      | Yes, n (%)               | No, n (%)|
|                                       |      | Yes, n (%)               |          |
| Age, years                            |      |                         |         |
| <50                                   | 2    | 2 (100)                  | 0       |
| 50-60                                 | 5    | 1 (20)                   | 4 (80)  |
| >60                                   | 23   | 9 (39)                   | 14 (61) |
| Carcinomatous component               |      |                         | 0.129^b |
| Endometrioid                          | 26   | 12 (46)                  | 14 (54) |
| Non-endometrioid                      | 4    | 0                        | 4 (100) |
| Myometrial invasion                   |      |                         | 0.722^b |
| Yes                                   | 16   | 7 (44)                   | 9 (56)  |
| No                                    | 14   | 5 (36)                   | 9 (64)  |
| Lymphovascular space invasion         |      |                         | 0.709^b |
| Yes                                   | 18   | 8 (44)                   | 10 (56) |
| No                                    | 12   | 4 (33)                   | 8 (67)  |
| Stage (FIGO)                          |      |                         | 0.234^a |
| I                                      | 11   | 4 (36)                   | 7 (64)  |
| II                                     | 6    | 3 (50)                   | 3 (50)  |
| III                                    | 7    | 1 (14)                   | 6 (86)  |
| IV                                     | 6    | 4 (67)                   | 2 (33)  |
| Presence of tumor in the oviduct      |      |                         | 0.391^b |
| Yes                                   | 7    | 4 (57)                   | 3 (43)  |
| No                                    | 23   | 8 (35)                   | 15 (65) |
| Grade                                 |      |                         | 0.204^a |
| G1                                     | 5    | 3 (60)                   | 2 (40)  |
| G2                                     | 7    | 1 (14)                   | 6 (86)  |
| G3                                     | 18   | 8 (44)                   | 10 (56) |
| Metastasis                            |      |                         | 1.0^b   |
|                | Yes | No  |
|----------------|-----|-----|
| Omental metastasis |     | 0.018^b |
| Yes             | 4   | 4 (100) |
| No              | 26  | 8 (31)  |

^aX^2-Pearson’s test; ^bFisher’s exact test. PCNA, proliferating cell nuclear antigen.
Table SII. Expression of MCM3 in relation to clinicopathological features within the carcinomatous component of uterine carcinosarcomas.

| Parameter                                | n   | Expression level of MCM3 | P-value |
|------------------------------------------|-----|--------------------------|---------|
|                                          |     | Yes, n (%) | No, n (%) |         |
| **Age, years**                           |     |            |           |         |
| <50                                      | 2   | 2 (100)  | 0         | 0.095^a |
| 50-60                                    | 5   | 0         | 5 (100)  |         |
| >60                                      | 23  | 3 (13)    | 20 (87)  |         |
| **Carcinomatous component**              |     |            |           | 0.611^b |
| Endometrioid                             | 26  | 9 (35)    | 17 (65)  |         |
| Non-endometrioid                         | 4   | 2 (50)    | 2 (50)   |         |
| **Myometrial invasion**                  |     |            |           | 1.0^b   |
| Yes                                      | 16  | 6 (37)    | 10 (63)  |         |
| No                                       | 14  | 5 (36)    | 9 (64)   |         |
| **Lymphovascular space invasion**        |     |            |           | 0.442^a |
| Yes                                      | 18  | 8 (44)    | 10 (56)  |         |
| No                                       | 12  | 3 (25)    | 9 (75)   |         |
| **Stage (FIGO)**                         |     |            |           | 0.0303^a|
| I                                        | 11  | 6 (55)    | 5 (45)   |         |
| II                                       | 6   | 1 (17)    | 5 (83)   |         |
| III                                      | 7   | 0         | 7 (100)  |         |
| IV                                       | 6   | 4 (67)    | 2 (33)   |         |
| **Presence of tumor in the oviduct**     |     |            |           | 0.371^b |
| Yes                                      | 7   | 4 (57)    | 3 (43)   |         |
| No                                       | 23  | 7 (30)    | 16 (70)  |         |
| **Grade**                                |     |            |           | 0.377^a |
| G1                                       | 5   | 1 (20)    | 4 (80)   |         |
|                | Yes       | 4 (33) | 8 (67) |
|----------------|-----------|--------|--------|
| Metastasis     | 12        |        |        |
| G2             | 7         | 4 (57) | 3 (43) |
| G3             | 18        | 6 (33) | 12 (67)|
| Omental metastasis | 4         | 4 (100)| 0      |
| Yes            | 12        | 4 (33) | 8 (67) |
| No             | 18        | 7 (39) | 11 (61)|
| No             | 26        | 7 (27) | 19 (73)|

\(^a\text{X}^2\text{-Pearson’s test}; \ ^b\text{Fisher’s exact test.}\)
Table SIII. Expression of topoIIα in relation to clinicopathological features within the carcinomatous component of uterine carcinosarcomas.

| Parameter                                      | n   | Expression level of topoIIα | P-value |
|------------------------------------------------|-----|----------------------------|---------|
|                                                |     | Yes, n (%)                 | No, n (%)|
| Age, years                                     |     |                            |         |
| <50                                            | 2   | 2 (100)                    | 0       |
| 50-60                                          | 5   | 2 (40)                     | 3 (60)  |
| ≥60                                            | 23  | 9 (39)                     | 14 (61) |
| Carcinomatous component                        |     |                            |         |
| Endometrioid                                   | 26  | 12 (46)                    | 14 (54) |
| Non-endometrioid                              | 4   | 1 (25)                     | 3 (75)  |
| Myometrial invasion                            |     |                            |         |
| Yes                                            | 16  | 4 (25)                     | 12 (75) |
| No                                             | 14  | 9 (64)                     | 5 (36)  |
| Lymphovascular space invasion                  |     |                            |         |
| Yes                                            | 18  | 6 (33)                     | 12 (67) |
| No                                             | 12  | 7 (58)                     | 5 (42)  |
| Stage (FIGO)                                   |     |                            |         |
| I                                              | 11  | 7 (64)                     | 4 (36)  |
| II                                             | 6   | 1 (17)                     | 5 (83)  |
| III                                            | 7   | 1 (14)                     | 6 (86)  |
| IV                                             | 6   | 4 (67)                     | 2 (33)  |
| Presence of tumor in the oviduct               |     |                            |         |
| Yes                                            | 7   | 4 (57)                     | 3 (43)  |
| No                                             | 23  | 9 (39)                     | 14 (61) |
| Grade                                          |     |                            |         |
| G1                                             | 5   | 4 (80)                     | 1 (20)  |
| G2                                             | 7   | 2 (29)                     | 5 (71)  |
| G3                                             | 18  | 7 (39)                     | 11 (61) |
| Metastasis                                     |     |                            | 1.0b    |
| Yes | 12 | 5 (42) | 7 (58) |
|-----|----|--------|--------|
| No  | 18 | 8 (44) | 10 (56) |
| Omental metastasis | | | 0.026<sup>b</sup> |
| Yes | 4  | 4 (100) | 0 |
| No  | 26 | 9 (35) | 17 (65) |

<sup>a</sup>X<sup>2</sup>-Pearson’s test; <sup>b</sup>Fisher’s exact test. topoIIα, topoisomerase IIα.